

**Author Contributions:** Dr Oh had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Suthiphosuwan, Sati, Bharatha, Oh.

**Acquisition, analysis, or interpretation of data:** All authors.

**Drafting of the manuscript:** Suthiphosuwan, Sati, Oh.

**Critical revision of the manuscript for important intellectual content:**

Suthiphosuwan, Absinta, Guenette, Reich, Bharatha, Oh.

**Statistical analysis:** Suthiphosuwan, Oh.

**Obtained funding:** Reich, Oh.

**Administrative, technical, or material support:** Suthiphosuwan, Sati, Guenette, Bharatha, Oh.

**Supervision:** Bharatha, Oh.

**Conflict of Interest Disclosures:** Dr Suthiphosuwan reported grants from Sanofi-Genzyme. Dr Reich reported having a cooperative research and development Vertex Pharmaceuticals outside the submitted work as well holding US Patents 9,607,392 (system and method of automatically detecting tissue abnormalities) and 9,888,876 (method of analyzing multi-sequence magnetic resonance imaging data for analyzing brain abnormalities in a participant). Dr Oh reported grants and personal fees from Biogen-Idec, Roche, and Sanofi-Genzyme as well as personal fees from Celgene, Novartis, and EMD-Serono. No other disclosures were reported.

**Funding/Support:** This study was funded by the MS Society of Canada and the St. Michael's Hospital Foundation Barford & Love Multiple Sclerosis Fund. The Intramural Program of the National Institute of Neurological Disorders and Stroke, part of the United States National Institutes of Health, also partially supported this research.

**Role of the Funder/Sponsor:** The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Contributions:** We thank Daniel Selchen, MD, St Michael's Hospital, for his contribution to this work, for which he was not compensated.

1. Okuda DT, Siva A, Kantarci O, et al; Radiologically Isolated Syndrome Consortium (RISC); Club Francophone de la Sclérose en Plaques (CFSEP). Radiologically isolated syndrome: 5-year risk for an initial clinical event. *PLoS One*. 2014;9(3):e90509. doi:10.1371/journal.pone.0090509

2. Kuhlmann T, Ludwin S, Prat A, Antel J, Brück W, Lassmann H. An updated histological classification system for multiple sclerosis lesions. *Acta Neuropathol*. 2017;133(1):13-24. doi:10.1007/s00401-016-1653-y

3. Absinta M, Sati P, Masuzzo F, et al. Association of chronic active multiple sclerosis lesions with disability in vivo [published online August 12, 2019]. *JAMA Neurol*. 2019. doi:10.1001/jamaneurol.2019.2399

4. Suthiphosuwan S, Sati P, Guenette M, et al. The central vein sign in radiologically isolated syndrome. *AJNR Am J Neuroradiol*. 2019;40(5):776-783. doi:10.3174/ajnr.A6045

5. Sati P, Oh J, Constable RT, et al; NAIMS Cooperative. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. *Nat Rev Neurol*. 2016;12(12):714-722. doi:10.1038/nrneurol.2016.166

6. Tallantyre EC, Dixon JE, Donaldson I, et al. Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions. *Neurology*. 2011;76(6):534-539. doi:10.1212/WNL.Ob013e31820b7630

## CORRECTION

**Correction to Collaborator's Name:** The Original Investigation titled "Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial,"<sup>1</sup> published online March 2, 2020, was corrected to fix the spelling of a collaborator's name to Katherine Moretz, which had been incorrectly given as Katherine Morteiz in the Group Members section. This article was corrected online.

1. Miller I, Scheffer IE, Gunning B, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial. *JAMA Neurol*. Published online March 2, 2020. doi:10.1001/jamaneurol.2020.0073

**Retracted Article in Reference Section:** In the Letter to the Editor "We Dropped the Reflex Hammer on Hypertension 20 Years Ago,"<sup>1</sup> the fifth reference was retracted on February 20, 2020. This article was corrected online.

1. Estol CJ. We dropped the reflex hammer on hypertension 20 years ago. *JAMA Neurol*. Published online March 2, 2020. doi:10.1001/jamaneurol.2020.0070

**Error in Labels for Number at Risk:** In the Original Investigation "Association of Levels of Specialized Care With Risk of Premature Mortality in Patients With Epilepsy,"<sup>1</sup> the labels for rows 1 and 3 for the number at risk in Figure 2 were switched. The first row label "Exposed to comprehensive epilepsy program care" was changed to "Unexposed to neurologist care." The third row labels "Unexposed to neurologist care" was changed to "Exposed to comprehensive epilepsy program care." This article was corrected online.

1. Lowerison MW, Josephson CB, Jetté N, et al. Association of levels of specialized care with risk of premature mortality in patients with epilepsy. *JAMA Neurol*. 2019;76(11):1352-1358. doi:10.1001/jamaneurol.2019.2268